Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16211713 | 0.91 | ALDH1A1 (0.41) | OPRM1SIGMAR1KCNH2KDM4EALDH1A1 | |
| SCHEMBL16211435 | 0.89 | HDAC1 (0.47) | OPRM1SIGMAR1KCNH2ALDH1A1 | |
| SCHEMBL16211419 | 0.89 | OPRM1 (0.43) | OPRM1SIGMAR1KCNH2 | |
| SCHEMBL22217688 | 0.88 | KDM4E (0.39) | OPRM1SIGMAR1KCNH2KDM4EALDH1A1 | |
| SCHEMBL22217687 | 0.88 | ALDH1A1 (0.41) | OPRM1SIGMAR1KCNH2KDM4EALDH1A1 | |
| SCHEMBL17618085 | 0.87 | ALDH1A1 (0.43) | KDM4EALDH1A1 | |
| SCHEMBL16211377 | 0.85 | KDM4E (0.39) | OPRM1SIGMAR1KCNH2KDM4EALDH1A1 | |
| SCHEMBL16211374 | 0.85 | KDM4E (0.39) | OPRM1SIGMAR1KCNH2KDM4EALDH1A1 | |
| SCHEMBL16211517 | 0.84 | ALDH1A1 (0.43) | OPRM1SIGMAR1KCNH2KDM4EALDH1A1 | |
| SCHEMBL16211730 | 0.82 | ALDH1A1 (0.53) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2016-03-24 | — | — | US | disclosed |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2016-03-24 | — | — | US | disclosed |
| EP-2991982-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014178606-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014178606-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | OPRM1 3134/4885SIGMAR1 2318/4885KCNH2 4510/4885 |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | OPRM1 3134/4885SIGMAR1 2318/4885KCNH2 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.